TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23543666

Group type: EXPERIMENTAL
Intervention: Vandetanib
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 21775560

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (daily vitamin C 120 mg, β-carotene 6 mg, vitamin E 30 mg, selenium 100 μg, zinc 20 mg)
Number of subjects: 4447

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 4447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4447
Study: 20023348

Group type: EXPERIMENTAL
Intervention: Dynamic Muscular Stabilization Techniques (DMST)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional treatment (electrotherapy and lumbar strengthening exercises)
Number of subjects: 102
Study: 17264975

Group type: EXPERIMENTAL
Intervention: Concentric isokinetic resistance training
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Eccentric isokinetic resistance training
Number of subjects: 70
Study: 14984920

Group type: EXPERIMENTAL
Intervention: Peak CK-MB ratios of 0-1xULN
Number of subjects: 2384

Group type: EXPERIMENTAL
Intervention: Peak CK-MB ratios of 1-3xULN
Number of subjects: 2384

Group type: EXPERIMENTAL
Intervention: Peak CK-MB ratios of 3-5xULN
Number of subjects: 2384

Group type: EXPERIMENTAL
Intervention: Peak CK-MB ratios of 5-10xULN
Number of subjects: 2384

Group type: EXPERIMENTAL
Intervention: Peak CK-MB ratios of >10xULN
Number of subjects: 2384

Group type: EXPERIMENTAL
Intervention: Continuous peak CK-MB ratio after PCI
Number of subjects: 2384
Study: 11686810

Group type: EXPERIMENTAL
Intervention: Ready-to-use Emdogain-gel
Number of subjects: 88

Group type: COMPARATOR
Intervention: Marketed Emdogain
Number of subjects: 88
Study: 9542288

Group type: EXPERIMENTAL
Intervention: Combination of plethysmography, vibrometry, two point discrimination, and monofilament testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various testing modalities utilized in the shipyard medical department
Number of subjects: 0
Study: 8147452

Group type: EXPERIMENTAL
Intervention: 5% CO2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7% CO2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Room-air hyperventilation
Number of subjects: 0
Study: 3166942

Group type: EXPERIMENTAL
Intervention: Grenz rays alone (4 Gy administered on six occasions at intervals of 1 week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Grenz rays combined with topical corticosteroid (betamethasone dipropionate)
Number of subjects: 40
Study: 29803341

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 442

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 442
Study: 28748334

Group type: EXPERIMENTAL
Intervention: Omega-3 and -6 supplementation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 25466700

Group type: EXPERIMENTAL
Intervention: Oral sildenafil 20 or 40 mg p.o. t.i.d. for 6 weeks
Number of subjects: 20
Study: 23915324

Group type: EXPERIMENTAL
Intervention: Public health messages delivered via email, fax, SMS (cell phone text messaging)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Control group (no messages received)
Number of subjects: 528
Study: 20886505

Group type: EXPERIMENTAL
Intervention: Single Pulse treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Double Pulse treatment
Number of subjects: 16
Study: 17653109

Group type: EXPERIMENTAL
Intervention: Alcohol taste cues
Number of subjects: 37

Group type: COMPARATOR
Intervention: Appetitive control
Number of subjects: 37
Study: 17042839

Group type: EXPERIMENTAL
Intervention: Mandated five-channel physiological monitoring
Number of subjects: 402

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 402
Study: 14639081

Group type: EXPERIMENTAL
Intervention: HIV self-care symptom management intervention (six home visits by registered nurses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 10820347

Group type: EXPERIMENTAL
Intervention: Breast irradiation
Number of subjects: 837

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 837
Study: 8840852

Group type: EXPERIMENTAL
Intervention: Ibutilide (1.0 and 0.5 mg or 1.0 and 1.0 mg)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 1531484

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg in fasting state
Number of subjects: 26

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg in nonfasting state
Number of subjects: 26
Study: 6372362

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (AMCA)
Number of subjects: 230
Study: 31922268

Group type: EXPERIMENTAL
Intervention: Machine learning approaches (support vector machines, random forest, extremely randomized tree, deep learning methods)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning models
Number of subjects: 0
Study: 29715303

Group type: EXPERIMENTAL
Intervention: TASSH + HIC
Number of subjects: 757

Group type: COMPARATOR
Intervention: HIC
Number of subjects: 757
Study: 27341450

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg) combined with lidocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine only
Number of subjects: 60
Study: 24836393

Group type: EXPERIMENTAL
Intervention: MK-3641 (1.5 Amb a 1-U)
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: MK-3641 (6 Amb a 1-U)
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: MK-3641 (12 Amb a 1-U)
Number of subjects: 1707

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: MK-3641 (all doses)
Number of subjects: 1707
Study: 23082208

Group type: EXPERIMENTAL
Intervention: Training and certification of pharmacy workers in STD syndrome management
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: Simulated patient evaluations
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: Pharmacy worker training
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: Continuing education for physicians and midwives
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: Educational support from Prevention Salespersons
Number of subjects: 1390
Study: 20227636

Group type: EXPERIMENTAL
Intervention: Optive eyedrops, used at least three times a day for one month
Number of subjects: 47

Group type: COMPARATOR
Intervention: Hylocomod eyedrops, used at least three times a day for one month
Number of subjects: 47
Study: 18729147

Group type: EXPERIMENTAL
Intervention: Internet delivered cognitive behavior therapy combined with five group exposure sessions (ICBT+ exp)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Internet program alone (ICBT)
Number of subjects: 38
Study: 16018754

Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 12634652

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (oral regimens with treatment durations of > or =7 days)
Number of subjects: 3969

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (general)
Number of subjects: 3969

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (low-risk patients)
Number of subjects: 3969

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (vaginal regimens)
Number of subjects: 3969

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment in patients with preterm labor
Number of subjects: 3969
Study: 10545551

Group type: EXPERIMENTAL
Intervention: Permissive hypercapnia (PHC; PaCO2: 45-55 mm Hg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Normocapnia (NC; PaCO2: 35-45 mm Hg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Permissive hypercapnia (PHC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Normocapnia (NC)
Number of subjects: 49
Study: 8768849

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD; 120 mg, orally)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combination of PD and Pirenzepine (PZP; 100 mg, orally)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 1992739

Group type: EXPERIMENTAL
Intervention: 1% apraclonidine hydrochloride preoperatively
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 1% apraclonidine hydrochloride postoperatively
Number of subjects: 38

Group type: COMPARATOR
Intervention: Artificial tears postoperatively
Number of subjects: 38
Study: 6637785

Group type: EXPERIMENTAL
Intervention: Cessation of cigarette smoking and lowered blood lipid levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antihypertensive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-adrenergic blocker prazosin
Number of subjects: 0
Study: 30919809

Group type: EXPERIMENTAL
Intervention: 15 mg/kg intravenous tranexamic acid dissolved in 100 mL of saline (TXA group)
Number of subjects: 176

Group type: COMPARATOR
Intervention: 100 mL of saline solution (placebo group)
Number of subjects: 176
Study: 28248799

Group type: EXPERIMENTAL
Intervention: Structured education and exercise program
Number of subjects: 41

Group type: COMPARATOR
Intervention: Routine clinical care
Number of subjects: 41
Study: 25922614

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (hospital-based mild group stretching and balance exercises)
Number of subjects: 130
Study: 23994183

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients (SP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 30
Study: 21673279

Group type: EXPERIMENTAL
Intervention: Adjunctive topiramate treatment (mean treatment duration = 282 days, titrated to a dose of 25 mg/kg/d with subsequent uptitration to a maximum of 60 mg/kg/d)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Adjunctive topiramate treatment
Number of subjects: 284
Study: 17538537

Group type: EXPERIMENTAL
Intervention: Fish oil containing parenteral nutrition (FO: Lipoplus: LCT40%-MCT50%-FO10%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard parenteral nutrition (STD: Lipofundin medium‐chain triglyceride (MCT): long‐chain triglyceride (LCT)50%-MCT50%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish oil containing parenteral nutrition (FO)
Number of subjects: 0
Study: 16842478

Group type: EXPERIMENTAL
Intervention: Insulin lispro mixture 25/75 (Mix 25/75)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 20
Study: 12850677

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (within 7 days after onset of symptoms)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Initial conservative treatment followed by delayed laparoscopic cholecystectomy (6 to 8 weeks later)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy
Number of subjects: 145
Study: 11350436

Group type: EXPERIMENTAL
Intervention: Oral lithium gamolenate (700 mg daily for 15 days)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous lithium gamolenate (0.28 g/kg)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: High-dose intravenous lithium gamolenate (0.84 g/kg)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous lithium gamolenate with haemolysis
Number of subjects: 278
Study: 9303285

Group type: EXPERIMENTAL
Intervention: Rocuronium infusion during propofol-nitrous oxide anaesthesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rocuronium infusion during isoflurane-nitrous oxide anaesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rocuronium clearance
Number of subjects: 20
Study: 8134777

Group type: EXPERIMENTAL
Intervention: Ivermectin 100 micrograms/kg single dose
Number of subjects: 44

Group type: COMPARATOR
Intervention: Benzyl benzoate 10% application
Number of subjects: 44
Study: 3560380

Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal vaccine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 55
Study: 29858911

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (40 mg)
Number of subjects: 25
Study: 26936417

Group type: EXPERIMENTAL
Intervention: Vaniprevir (300 mg twice daily) + peginterferon alfa-2b + ribavirin for 12 weeks
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Vaniprevir (300 mg twice daily) + peginterferon alfa-2b + ribavirin for 24 weeks
Number of subjects: 93
Study: 24304363

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 19
Study: 23269509

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia with remifentanil (n=18)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia with remifentanil (n=19)
Number of subjects: 37
Study: 21056658

Group type: EXPERIMENTAL
Intervention: Sugar esters proniosomes (SEs) for transdermal delivery of vinpocetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral tablet of vinpocetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sugar esters proniosomes (SEs)
Number of subjects: 0
Study: 18003811

Group type: EXPERIMENTAL
Intervention: Fluad (with MF59 adjuvant)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Agrippal (without adjuvant)
Number of subjects: 256
Study: 16575382

Group type: EXPERIMENTAL
Intervention: Propofol (PROP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: MID\PROP\REMI
Number of subjects: 200
Study: 14556923

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg per day)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Anastrozole (1 mg per day)
Number of subjects: 713
Study: 11071843

Group type: EXPERIMENTAL
Intervention: Aerobic activity group
Number of subjects: 174

Group type: COMPARATOR
Intervention: Stretching and toning group
Number of subjects: 174
Study: 8679345

Group type: EXPERIMENTAL
Intervention: General anaesthesia with mechanical ventilation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conscious, spontaneous breathing
Number of subjects: 26
Study: 1580636

Group type: EXPERIMENTAL
Intervention: Methionine-deprived amino acid solution (AO-90)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional amino acid solution (control group)
Number of subjects: 0
Study: 3022852

Group type: EXPERIMENTAL
Intervention: C.O.P.A.C. combination (Cyclophosphamide, Vincristine, Cis‐Platinum, Adriamycin and CCNU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 0
Study: 29042033

Group type: EXPERIMENTAL
Intervention: 3D‐SC1® (Intervention group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: DVD (Control group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Comparison of 3D‐SC1® and DVD training
Number of subjects: 96
Study: 26567858

Group type: EXPERIMENTAL
Intervention: Effective CPAP
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 103
Study: 24444469

Group type: EXPERIMENTAL
Intervention: Telemedicine screening with remote retinal photography
Number of subjects: 511

Group type: COMPARATOR
Intervention: Outpatient binocular indirect ophthalmoscope examinations
Number of subjects: 511
Study: 22146780

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for 10 weeks in addition to best medical care
Number of subjects: 11

Group type: COMPARATOR
Intervention: Best medical care (control group)
Number of subjects: 11
Study: 20659341

Group type: EXPERIMENTAL
Intervention: Computerized decision aid (DA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 18328872

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for PTSD
Number of subjects: 131
Study: 17198647

Group type: EXPERIMENTAL
Intervention: Torasemide (5 mg/day) at bedtime
Number of subjects: 58

Group type: COMPARATOR
Intervention: Torasemide (5 mg/day) upon awakening
Number of subjects: 58
Study: 14571073

Group type: COMPARATOR
Intervention: Medium-dose UVA1 phototherapy (48 J/cm2), treated 4 times a week for 5 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control skin (not specified how it was treated).
Number of subjects: 0
Study: 10910446

Group type: COMPARATOR
Intervention: Conventional (potentially microbiologically contaminated) dialysate (group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Online-produced ultrapure dialysate (group II)
Number of subjects: 30
Study: 8923573

Group type: EXPERIMENTAL
Intervention: Dihydroergocristine (2 x 3 mg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Dihydroergocristine
Number of subjects: 56
Study: 1571080

Group type: EXPERIMENTAL
Intervention: Madopar HBS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sinemet CR4
Number of subjects: 20
Study: 4093974

Group type: EXPERIMENTAL
Intervention: Type A children during cognitive challenge
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Type A children under ambiguous performance standards
Number of subjects: 87

Group type: COMPARATOR
Intervention: Type B children during cognitive challenge
Number of subjects: 87
Study: 31433997

Group type: COMPARATOR
Intervention: Tobramycin inhalation powder (TIP) administered in three different daily doses as continuous or cyclical regimens for 112 days of double-blind treatment.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo administered in a double-blind manner for 112 days of treatment.
Number of subjects: 180
Study: 29085540

Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Per-protocol analysis
Number of subjects: 0
Study: 26040175

Group type: EXPERIMENTAL
Intervention: Hard acrylic based resins
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Silicone‐based soft liner
Number of subjects: 24
Study: 23086134

Group type: EXPERIMENTAL
Intervention: Tolterodine (group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Trospium chloride (group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oxybutynin (group C)
Number of subjects: 90
Study: 22228885

Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate (LOLA) infusion
Number of subjects: 623
Study: 19370275

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 mcg.kg‐1 during induction
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 mcg.kg‐1 during induction and Propofol 1 mg.kg‐1 at the end of surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline at the end of surgery (Control)
Number of subjects: 120
Study: 16820557

Group type: EXPERIMENTAL
Intervention: BMC group (CABG and injection of 60.10(6)+/‐31.10(6) BMC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CABG only)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BMC group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 12628557

Group type: EXPERIMENTAL
Intervention: Telephone instructions in chest compressions alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard CPR including mouth-to-mouth ventilation
Number of subjects: 20
Study: 11126523

Group type: EXPERIMENTAL
Intervention: Primary total hip arthroplasty (THA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Osteosynthesis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nutritional support (protein- and energy-enriched food)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nutritional status (measured by serum albumin levels)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pain assessment
Number of subjects: 100
Study: 9093250

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 80
Study: 1609761

Group type: EXPERIMENTAL
Intervention: Zinc (25 mg/d)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Vitamin A (1500 RE/d)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Zinc plus Vitamin A
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 3877282

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Methohexitone (2 mg/kg)
Number of subjects: 73
Study: 31481323

Group type: EXPERIMENTAL
Intervention: Surgery for closed ankle fractures with antibiotic prophylaxis
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Age (per 10 years)
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Age squared (per 10 years)
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: BMI (per kg/m2)
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Charlson comorbidity index ≥2 vs. 0
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Charlson comorbidity index 1 vs. 0
Number of subjects: 998
Study: 29174706

Group type: EXPERIMENTAL
Intervention: Severe and non-acute ischemia
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Non-severe and non-acute ischemia
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Non-severe and acute ischemia
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Severe and acute ischemia
Number of subjects: 85

Group type: COMPARATOR
Intervention: Inferior STEMI
Number of subjects: 85
Study: 28840325

Group type: EXPERIMENTAL
Intervention: Single-bundle (SB) technique
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) technique
Number of subjects: 31

Group type: COMPARATOR
Intervention: Preoperative to 6 months postoperative results (both groups)
Number of subjects: 31

Group type: COMPARATOR
Intervention: IKDC score, Lysholm score, Tegner activity scale, anterior drawer test (both groups)
Number of subjects: 31
Study: 26328937

Group type: EXPERIMENTAL
Intervention: Hydrosorb®
Number of subjects: 278

Group type: COMPARATOR
Intervention: Water based spray (control)
Number of subjects: 278
Study: 23756701

Group type: EXPERIMENTAL
Intervention: High activity neutral protease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral protease NB GMP grade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thermolysin
Number of subjects: 0
Study: 21051425

Group type: EXPERIMENTAL
Intervention: 10 mL PRP (10 times higher platelet concentration than peripheral blood)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (14 patients, no PRP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mL PRP
Number of subjects: 30
Study: 18444145

Group type: EXPERIMENTAL
Intervention: Tomato products (no soy) for Weeks 0 through 4, targeting a minimum of 25 mg of lycopene/day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Soy (no tomatoes) for Weeks 0 through 4, providing 40 g of soy protein/day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combined tomato-rich diet and soy supplements for Weeks 4 through 8
Number of subjects: 41